Countries where we have Access to Medicines programs

- 48 LMICs where we are actively improving access to medicines
- 3,487 patients involved in our Patient Assistance Programs

Our Access to Medicines approach

- Patient journey
  - Education
  - Screening
  - Diagnosis
  - Treatment
  - Aftercare

Guided by core Access principles

- Patient first
  - Providing access to medicines and vaccines where and when they are needed most

- Holistic
  - Addressing barriers to access from beginning through the patient journey

- Collaborative
  - Building and supporting sustainable health care systems through diverse partnerships and information sharing

Broadened patient access

- 188,782 patients screened
- 16,432 patients diagnosed

Increased health care capacity

- 4,459 health care professionals trained
- 1,796 community health volunteers trained

Strengthened health care systems

- > 2,000 scientific instruments and medical equipment shared
- > 1,000 research projects and clinical trials addressing local health inequities

Our future priorities

- Broadening access
  - Expand our innovative financing models and affordability programs, and leveraging digital capabilities
  - Deepen local policy engagement and shape discussions on key health care system priorities
  - Drive local capacity building, informed by global best practices, to address barriers to access

- Unlocking societal value through partnerships
  - Expand Blueprint initiative into new markets to address gaps in health care capabilities and delivery
  - Drive collective impact measurement through Access to Health Guidebook and Frameworks
  - Equip local governments and actors to own and drive efforts for continuity and sustainability

- Integrating our business approach
  - Embed whole-of-organization approach to addressing access barriers, with shared responsibility across the business
  - Leverage our Center of Excellence model to accelerate internal capacity building
  - Empower local teams to deliver on access priorities through clear ownership and incentives

We’re very proud of the progress we’ve made over the past two years to broaden access to medicines, particularly in view of the challenges posed by the COVID-19 pandemic. Together with our partners, we’ve acted on our commitment to strengthen local health care systems and address barriers to access at each stage of the patient journey.

48 LMICs

1 These countries with evolving health care systems have been specifically identified as ‘Access Countries’ whereby the business strategy is focused on pro-actively investing to strengthen health care systems

2 Based on Takeda’s internal data